Response to "Re. Analysis of the Elective Treatment Process for Critical Limb Ischaemia with Tissue Loss : Diabetic Patients Require Rapid Revascularisation" by Noronen, Katariina & Venermo, Maarit
CORRESPONDENCE
Re “Analysis of the Elective Treatment Process for Critical
Limb Ischaemia with Tissue Loss: Diabetic Patients Require
Rapid Revascularisation”
*Corresponding author. A-block Parish Building, University
Hospital North Midlands NHS Trust, Royal Stoke Hospitals,
Stoke on Trent ST46QG, UK.
Email-address: surgeryram@doctors.org.uk (S. Rajagopalan)
Available online 30 March 2017
Crown Copyright  2017 Published by Elsevier Ltd on behalf
of European Society for Vascular Surgery. All rights
reserved.
http://dx.doi.org/10.1016/j.ejvs.2017.02.030
DOI of original article: http://dx.doi.org/10.1016/
j.ejvs.2016.10.023
Response to “Re. Analysis of the Elective Treatment
Process for Critical Limb Ischaemia with Tissue Loss:
Diabetic Patients Require Rapid Revascularisation”
Eur J Vasc Endovasc Surg (2017) 53, 755e756We read with interest this article by Noronen et al.1 in
EJVES in our weekly journal club. We wish to make some
comments on this paper.
This is a retrospective analysis in 2017 of data collected 6
years ago for a single centre using a single vascular con-
sultant’s database. The aim was to recognise reasons for
“delay” in the elective treatment of critical ischaemia, by
following patients through their treatments over 2 years.
The results showed comparative “delay” in treatments
regardless of their treatments however, but does not
answer the primary outcome “to analyse the treatment
process from referral to revascularisation, to discover
possible delays and reasons behind them, and to distinguish
patients beneﬁtting the most from early revascularisation.”
Instead it compared the information of their diabetic pa-
tients versus other patients without critical ischaemia. The
paper would have been more attractive if it had evaluated
the reasons for “delay” in patient treatment, or for that
matter, if it had clariﬁed and quantiﬁed the delay or in
which part of the pathway the delay was; for example,
onset of ulcer to primary care or primary care to vascular
services, or in the vascular surgery department itself. Sub-
group comparisons or analysis were not set out in the aim
of the study.
While the results are shown in colourful diagrams, they
are difﬁcult to comprehend because of their complexity.
Figure 4 would have beneﬁtted greatly from a “number at
risk table” below the graph. This would also have shown the
attrition clearly in a retrospective data analysis.
The discussion section does admit the difﬁculties often
encountered in a retrospective study. The concluding
paragraph went too far from the objective in stating that
open revascularisation was better than the endovascular
method, which was not the objective of the study.
Overall, the study, though well intended, does not have
strong grounds to change any practice and has pitfalls in its
sections.
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University Hospital North Midlands NHS Trust, Royal Stoke
Hospitals, Stoke on Trent, UKWe thank the authors of this letter for taking an interest in
our study. Nevertheless, we wish to clarify few of the
addressed issues.
The aim of our study was to analyse the whole treatment
process, but the main focus was on wound healing, and the
number of emergency procedures and major amputations
and deaths during follow-up, outcomes that represent
possible consequences of delay.
We presented the structure of delay from referral to
revascularisation in Fig. 3. The Introduction described our
aim of 1 week from referral to ﬁrst visit, and 2 weeks from
decision to revascularisation, both target times we slightly
missed with a median of 9 and 18 days respectively. Imaging
studies took another 2 weeks. Finding causes behind these
delays was indeed our initial objective, yet no causes are
listed in the publication, simply because none were found.
No single step was excessively long, rather every step
should be slightly shortened. We also emphasized the
importance of pre-hospital delay, even if underlying causes
could not be obtained retrospectively. The delay in our
treatment was caused solely by the lack of available elective
time slots, for the ﬁrst vacant time was scheduled at each
step. Therefore, rather than looking for reasons, we feel that
establishing the existence of delay is an important ﬁnding.
We also encourage other institutions to take a closer look at
their own treatment pathways, perhaps not to change
anyone’s practice, but to recognise and minimise the
“invisible delays.”
And ﬁnally, even if it wasn’t our primary focus, we could
not disregard the superior limb salvage and wound healing
after open surgery, both ﬁndings we wanted to raise in this
“endovascular era”.
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